| KPI | [EUR m] | Q2 2025 | FY 2025 | Q2 2026 E | FY 2026 E | FY 2027 E | FY 2028 E |
|---|---|---|---|---|---|---|---|
| Pure Flow Processing, Sales | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Pure Flow Processing, Sales | Highest | 512.6 | 2,087.4 | 2,221.9 | 2,338.3 | ||
| Pure Flow Processing, Sales | Consensus (Mean) | 469.5 | 1,953.1 | 492.5 | 2,032.5 | 2,132.8 | 2,224.2 |
| Pure Flow Processing, Sales | Median | 488.0 | 2,030.7 | 2,125.0 | 2,218.1 | ||
| Pure Flow Processing, Sales | Lowest | 485.1 | 2,010.0 | 2,091.0 | 2,175.0 | ||
| Pure Flow Processing, EBITDA before restructuring | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Pure Flow Processing, EBITDA before restructuring | Highest | 146.1 | 582.6 | 618.6 | 654.7 | ||
| Pure Flow Processing, EBITDA before restructuring | Consensus (Mean) | 131.5 | 522.4 | 136.0 | 552.8 | 585.3 | 615.4 |
| Pure Flow Processing, EBITDA before restructuring | Median | 134.0 | 555.9 | 587.9 | 617.0 | ||
| Pure Flow Processing, EBITDA before restructuring | Lowest | 132.0 | 525.0 | 542.0 | 569.0 | ||
| Pure Flow Processing, EBITDA before restructuring margin in % | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Pure Flow Processing, EBITDA before restructuring margin in % | Highest | 28.6 | 27.9 | 28.1 | 28.3 | ||
| Pure Flow Processing, EBITDA before restructuring margin in % | Consensus (Mean) | 28.0 | 26.7 | 27.6 | 27.2 | 27.4 | 27.7 |
| Pure Flow Processing, EBITDA before restructuring margin in % | Median | 27.5 | 27.4 | 27.5 | 27.8 | ||
| Pure Flow Processing, EBITDA before restructuring margin in % | Lowest | 26.5 | 25.7 | 25.5 | 25.7 | ||
| Nutrition Plant Engineering, Sales | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Nutrition Plant Engineering, Sales | Highest | 495.0 | 2,111.4 | 2,248.6 | 2,406.0 | ||
| Nutrition Plant Engineering, Sales | Consensus (Mean) | 449.9 | 1,954.6 | 476.0 | 2,071.2 | 2,178.8 | 2,274.6 |
| Nutrition Plant Engineering, Sales | Median | 474.7 | 2,081.7 | 2,202.8 | 2,282.3 | ||
| Nutrition Plant Engineering, Sales | Lowest | 459.3 | 2,004.0 | 2,070.0 | 2,132.0 | ||
| Nutrition Plant Engineering, EBITDA before restructuring | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Nutrition Plant Engineering, EBITDA before restructuring | Highest | 59.4 | 253.4 | 279.8 | 309.3 | ||
| Nutrition Plant Engineering, EBITDA before restructuring | Consensus (Mean) | 45.2 | 222.4 | 50.8 | 242.7 | 261.0 | 278.3 |
| Nutrition Plant Engineering, EBITDA before restructuring | Median | 49.8 | 243.9 | 264.8 | 279.7 | ||
| Nutrition Plant Engineering, EBITDA before restructuring | Lowest | 47.2 | 223.0 | 235.0 | 247.9 | ||
| Nutrition Plant Engineering, EBITDA before restructuring margin in % | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Nutrition Plant Engineering, EBITDA before restructuring margin in % | Highest | 12.0 | 12.0 | 12.5 | 13.3 | ||
| Nutrition Plant Engineering, EBITDA before restructuring margin in % | Consensus (Mean) | 10.0 | 11.4 | 10.7 | 11.7 | 12.0 | 12.2 |
| Nutrition Plant Engineering, EBITDA before restructuring margin in % | Median | 10.5 | 11.8 | 12.0 | 12.3 | ||
| Nutrition Plant Engineering, EBITDA before restructuring margin in % | Lowest | 10.0 | 11.1 | 11.3 | 11.4 | ||
| Pharma & Food Applications, Sales | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Pharma & Food Applications, Sales | Highest | 279.2 | 1,132.0 | 1,212.6 | 1,354.4 | ||
| Pharma & Food Applications, Sales | Consensus (Mean) | 262.2 | 1,058.3 | 274.3 | 1,113.8 | 1,174.3 | 1,239.2 |
| Pharma & Food Applications, Sales | Median | 274.0 | 1,116.2 | 1,180.7 | 1,239.7 | ||
| Pharma & Food Applications, Sales | Lowest | 268.3 | 1,090.2 | 1,139.0 | 1,184.9 | ||
| Pharma & Food Applications, EBITDA before restructuring | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Pharma & Food Applications, EBITDA before restructuring | Highest | 39.7 | 164.0 | 179.0 | 196.3 | ||
| Pharma & Food Applications, EBITDA before restructuring | Consensus (Mean) | 34.6 | 140.7 | 37.3 | 155.9 | 169.5 | 183.3 |
| Pharma & Food Applications, EBITDA before restructuring | Median | 37.6 | 157.8 | 173.6 | 188.1 | ||
| Pharma & Food Applications, EBITDA before restructuring | Lowest | 35.0 | 138.0 | 144.0 | 158.0 | ||
| Pharma & Food Applications, EBITDA before restructuring margin in % | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Pharma & Food Applications, EBITDA before restructuring margin in % | Highest | 14.5 | 14.5 | 15.1 | 15.5 | ||
| Pharma & Food Applications, EBITDA before restructuring margin in % | Consensus (Mean) | 13.2 | 13.3 | 13.6 | 14.0 | 14.4 | 14.8 |
| Pharma & Food Applications, EBITDA before restructuring margin in % | Median | 13.6 | 14.2 | 14.8 | 15.2 | ||
| Pharma & Food Applications, EBITDA before restructuring margin in % | Lowest | 12.8 | 12.6 | 12.6 | 13.3 | ||
| Farm Technologies, Sales | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Farm Technologies, Sales | Highest | 207.8 | 821.0 | 878.8 | 935.9 | ||
| Farm Technologies, Sales | Consensus (Mean) | 182.3 | 763.4 | 194.9 | 804.0 | 841.1 | 875.4 |
| Farm Technologies, Sales | Median | 195.1 | 805.0 | 837.0 | 871.9 | ||
| Farm Technologies, Sales | Lowest | 183.3 | 783.3 | 805.7 | 825.9 | ||
| Farm Technologies, EBITDA before restructuring | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Farm Technologies, EBITDA before restructuring | Highest | 34.1 | 134.6 | 149.6 | 163.6 | ||
| Farm Technologies, EBITDA before restructuring | Consensus (Mean) | 26.3 | 113.0 | 30.7 | 127.4 | 135.9 | 144.8 |
| Farm Technologies, EBITDA before restructuring | Median | 30.1 | 127.0 | 134.7 | 146.0 | ||
| Farm Technologies, EBITDA before restructuring | Lowest | 28.0 | 119.2 | 124.1 | 130.1 | ||
| Farm Technologies, EBITDA before restructuring margin in % | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Farm Technologies, EBITDA before restructuring margin in % | Highest | 17.0 | 16.5 | 17.3 | 17.5 | ||
| Farm Technologies, EBITDA before restructuring margin in % | Consensus (Mean) | 14.4 | 14.8 | 15.7 | 15.9 | 16.2 | 16.5 |
| Farm Technologies, EBITDA before restructuring margin in % | Median | 16.0 | 16.0 | 16.2 | 16.6 | ||
| Farm Technologies, EBITDA before restructuring margin in % | Lowest | 14.5 | 14.8 | 14.8 | 14.9 | ||
| Consolidation/Other, Sales | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Consolidation/Other, Sales | Highest | -52.2 | -230.0 | -220.0 | -215.0 | ||
| Consolidation/Other, Sales | Consensus (Mean) | -52.1 | -234.0 | -57.1 | -237.3 | -241.5 | -246.6 |
| Consolidation/Other, Sales | Median | -58.0 | -234.0 | -240.0 | -240.0 | ||
| Consolidation/Other, Sales | Lowest | -60.0 | -250.0 | -262.1 | -280.0 | ||
| Consolidation/Other, EBITDA before restructuring | Number of Estimates | 9 | 11 | 11 | 11 | ||
| Consolidation/Other, EBITDA before restructuring | Highest | -11.0 | -51.0 | -43.0 | -43.0 | ||
| Consolidation/Other, EBITDA before restructuring | Consensus (Mean) | -20.9 | -91.1 | -20.7 | -89.6 | -90.5 | -91.9 |
| Consolidation/Other, EBITDA before restructuring | Median | -21.0 | -90.5 | -90.5 | -92.7 | ||
| Consolidation/Other, EBITDA before restructuring | Lowest | -26.4 | -111.0 | -115.0 | -120.0 |
This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.
